ABI H0731

Drug Profile

ABI H0731

Alternative Names: ABI-H0731

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 26 Jul 2018 ABI H0731 receives Fast Track designation for Hepatitis B [PO,Tablet] (Adjunctive treatment, Treatment-experienced) in USA
  • 26 Jul 2018 ABI H0731 receives Fast Track designation for Hepatitis B [PO,Tablet] (Combination therapy, Treatment-naive) in USA
  • 19 Jun 2018 Phase-II clinical trials in Hepatitis B (Combination therapy, Treatment-naive) in USA (PO) (NCT03577171)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top